Evidence map›Paper›PMID 34549772›Full record

ArticleRheumatology (Oxford, England)2021

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.

Mark C Genovese, Eduardo Mysler, Tetsuya Tomita, Kim A Papp, Carlo Salvarani, Sergio Schwartzman, Gaia Gallo, Himanshu Patel, Jeffrey R Lisse, Andris Kronbergs and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Mark C GenoveseDepartment of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
Eduardo MyslerOrganización Medica de Investigación, Buenos Aires, Argentina.
Tetsuya TomitaDepartment of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Kim A PappClinical Research and Probity Medical Research Inc., Waterloo, and the University of Toronto, Toronto, Canada.
Carlo SalvaraniAzienda USL-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Modena, Emilia-Romagna, Italy.
Sergio SchwartzmanDepartment of Medicine, The Hospital for Special Surgery, New York, NY.
Gaia GalloEli Lilly and Company, Indianapolis, IN, USA.
Himanshu PatelEli Lilly and Company, Indianapolis, IN, USA.
Jeffrey R LisseEli Lilly and Company, Indianapolis, IN, USA.
Andris KronbergsEli Lilly and Company, Indianapolis, IN, USA.
Soyi Liu LeageEli Lilly and Company, Indianapolis, IN, USA.
David H AdamsEli Lilly and Company, Indianapolis, IN, USA.
Wen XuEli Lilly and Company, Indianapolis, IN, USA.
Helena Marzo-OrtegaNIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, UK.
Mark G LebwohlDepartment of Dermatology, Mount Sinai Hospital, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34549772
PMCPMC8566904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.